Hepatotoxicity associated with non-steroidal anti-inflammatory drugs (Q35184567)

7 August 2017

1 reference

title

Hepatotoxicity associated with non-steroidal anti-inflammatory drugs (English)

1 reference

7 August 2017

1 reference

2

Geoffrey C Farrell

1 reference

7 August 2017

1

Narci C Teoh

1 reference

7 August 2017

1 May 2003

1 reference

7 August 2017

Clinics in liver disease

1 reference

7 August 2017

7

1 reference

7 August 2017

2

1 reference

7 August 2017

401-413

1 reference

The role of non-steroidal anti-inflammatory drugs in acute liver injury

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Anti-inflammatory drugs and variceal bleeding: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

COX 2 inhibitor and fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Adverse reactions to non-steroidal antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Active chronic hepatitis after chlorpromazine ingestion

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Incidence of Reye's syndrome in France: a hospital-based survey

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Reye's syndrome in the United States from 1981 through 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Ticlopidine-induced cholestatic hepatitis: report of three cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Ticlopidine-induced prolonged cholestasis: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Successful use of clopidogrel for cerebrovascular accident in a patient with suspected ticlopidine-induced hepatotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Clopidogrel-induced mixed hepatocellular and cholestatic liver injury

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Indomethacin-associated cholestasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Acute cholangitis and pancreatitis associated with sulindac (clinoril).

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Lymphopenia and hepatic toxicity with ibuprofen

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Subfulminant hepatitis requiring liver transplantation following ibuprofen overdose

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Hepatotoxicity following the therapeutic use of antipyretic analgesics

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Jaundice associated with naproxen

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

IBUFENAC (4-ISOBUTYLPHENYL ACETIC ACID).

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

IBUFENAC IN THE TREATMENT OF ARTHRITIS

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Fatal cholestatic jaundice in elderly patients taking benoxaprofen

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Biochemical and cellular mechanisms of toxic liver injury

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Oxaprozin-induced symptomatic hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Oxaprozin-induced fulminant hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Diclofenac-associated hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Diclofenac associated hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Cholestatic jaundice with skin desquamation in a 12-year-old girl.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Fatal hepatitis associated with diclofenac

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Inadvertent diclofenac rechallenge from generic and non-generic prescribing, leading to liver transplantation for fulminant liver failure

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Bromfenac (Duract)-associated hepatic failure requiring liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Severe hepatotoxicity associated with bromfenac sodium

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Hepatotoxicity associated with piroxicam use

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Piroxicam induced submassive necrosis of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Acute liver injury and droxicam use in the region of Friuli-Venezia Giulia

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Tenoxicam-associated hepatic injury: a case report and review

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

The "aspirin" of the new millennium: cyclooxygenase-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Celecoxib-induced acute pancreatitis and hepatitis: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Celecoxib-induced cholestatic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Drug Points: Cholestatic hepatitis in association with celecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Acute hepatocellular and cholestatic injury in a patient taking celecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Practical Issues in the Management of Hypersensitivity Reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Fatal hepatitis and renal failure during treatment with nimesulide

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Nimesulide-induced acute hepatitis: evidence from six cases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Fatal hepatitis associated with nimesulide.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Fatal intrahepatic cholestasis and interstitial lung fibrosis following gold therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Fatal hepatic necrosis associated with parenteral gold therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Fatal cholestatic hepatitis caused by D-penicillamine

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Cholestatic hepatitis caused by penicillamine

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

Serious liver disease in a patient receiving methotrexate and leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900022-9

7 January 2021

10.1016/S1089-3261(03)00022-9

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12879991